7-Methoxyflavone

CAS No. 22395-22-8

7-Methoxyflavone( —— )

Catalog No. M21235 CAS No. 22395-22-8

7-Methoxyflavone isolated from Zornia brasiliensis with antinociceptive effects.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG 37 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    7-Methoxyflavone
  • Note
    Research use only, not for human use.
  • Brief Description
    7-Methoxyflavone isolated from Zornia brasiliensis with antinociceptive effects.
  • Description
    7-Methoxyflavone isolated from Zornia brasiliensis with antinociceptive effects.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    22395-22-8
  • Formula Weight
    252.26
  • Molecular Formula
    C16H12O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (396.42 mM)
  • SMILES
    COc1ccc2c(c1)oc(cc2=O)-c1ccccc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Antinociceptive effect of 7-methoxyflavone isolated from Zornia brasiliensis[J]. Natural Product Letters 2013 27(18):1695-1699.
molnova catalog
related products
  • GRP (18-27) (human, ...

    Neuromedin C porcine (GRP, 18-27, porcine) is a bombesin-like neuropeptide that can be obtained from porcine spinal cord. Neuromedin C porcine exhibits a potent contractile activity on rat uterus in the characteristic manner of bombesin. Neuromedin C porcine has research potential for neurological-related diseases.

  • Berberine Impurity 8

    Berberine Impurity 8

  • Remimazolam

    Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?